Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2398078 | 0.70 | SLC6A5 (0.44) | SLC6A5ACHEGDAMAPT | |
| SCHEMBL3869244 | 0.68 | GRM5 (0.31) | — | |
| SCHEMBL2842994 | 0.67 | IKBKB (0.46) | — | |
| SCHEMBL14999681 | 0.67 | PDPK1 (0.37) | GDA | |
| SCHEMBL18785375 | 0.63 | SLC6A5 (0.48) | SLC6A5ACHEGDAMAPT | |
| Xanthine SCHEMBL28383484 | 0.62 | GDA (0.82) | ACHEGDAMAPT | |
| SCHEMBL29385750 | 0.61 | ERAP1 (0.61) | SLC6A5ACHEGDAMAPT | |
| SCHEMBL48258 | 0.61 | ERAP1 (0.61) | SLC6A5ACHEGDAMAPT | |
| Xanthine SCHEMBL28324466 | 0.60 | GDA (0.77) | ACHEGDAMAPT | |
| SCHEMBL26779045 | 0.60 | SLC6A5 (0.42) | SLC6A5ACHEGDAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050004133-A1 | Modulators of VR1 receptor | VERTEX PHARMACEUTICALS INCORPORATED | 2005-01-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004133-A1 | Modulators of VR1 receptor | TRPV1, TRPV2, TRPV3 | SLC6A5 1049/4885ACHE 4285/4885GDA 4295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.